Search Results
Nov 27, 2025, 11:12 ET Post Malone Thanksgiving Halftime Show To Kick Off The Salvation Army's Annual Red Kettle Campaign
with more than 7,400 centers of operation, The Salvation Army faces a unique challenge this year. "For nearly three decades, the Dallas Cowboys and the Gene and Jerry Jones family have stood alongside The Salvation Army, helping us bring hope and care to our neighbors in need," said Commissioner Merle Heatwole,
More news about: The Salvation Army
Nov 27, 2025, 11:12 ET El espectáculo de medio tiempo del Día de Acción de Gracias de Post Malone dará inicio a la Campaña Red Kettle anual del Ejército de Salvación
directos del país, con más de 7,400 centros de operación, y enfrenta un desafío único este año. «Durante casi tres décadas, los Dallas Cowboys y la familia Gene y Jerry Jones han estado junto al Ejército de Salvación, ayudándonos a brindar esperanza y atención a nuestros vecinos necesitados», declaró el comisionado
More news about: The Salvation Army
Nov 27, 2025, 10:01 ET Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease Innovation, Gene Therapies & Precision Medicine Reshape Global Healthcare
propelling this market:1. Record Growth in Gene & Cell Therapy Approvals (2023–2025)2023–2025 witnessed a sharp rise in FDA and EMA approvals for AAV-based gene therapies, CAR-T treatments, RNA-targeting medicines, and ex vivo gene-modified cell therapies, many of which address rare
More news about: DataM Intelligence 4 Market Research LLP
Nov 27, 2025, 06:45 ET In-Silico Clinical Trials Market Set to Reach USD 6.39 Billion by 2033 as Pharma and MedTech Accelerate Digital-First Validation, AI Modeling & Virtual Patient Simulations
risk, optimize protocols, and predict patient responses drove rapid IST integration across small-molecule, biologics, RNA therapies, and cell & gene therapy pipelines.Medical Device ManufacturersMedical device companies accounted for 29% (USD 1.15 billion). These firms
More news about: DataM Intelligence 4 Market Research LLP
Nov 27, 2025, 06:30 ET Intratumoral Cancer Therapies Market to Reach USD 630.7 Million by 2033 as Next-Generation Localized Immunotherapies Transform Solid Tumor Treatment
and minimizes systemic side effects.The growing clinical validation of intratumoral immunotherapies, including oncolytic viruses, adenoviral gene-delivery platforms, STING agonists, and localized immunomodulators, has significantly accelerated the adoption of this treatment approach. These
More news about: DataM Intelligence 4 Market Research LLP
Nov 27, 2025, 05:02 ET L'Agence européenne des médicaments (EMA) accorde la désignation de médicament orphelin au traitement dérivé du plasma de Kedrion contre l'acéruloplasminémie congénitale, une maladie génétique rare du métabolisme du fer
L'acéruloplasminémie est une maladie autosomique récessive causée par des mutations du gène CP, entraînant un déficit ou une absence de céruloplasmine, une protéine plasmatique essentielle au transport du fer. En l'absence de traitement, le
More news about: Kedrion
Nov 27, 2025, 04:00 ET European Medicines Agency (EMA) grants Orphan Drug Designation to Kedrion's plasma-derived treatment for Congenital Aceruloplasminemia, a rare genetic disorder of iron metabolism
Aceruloplasminemia is an autosomal recessive disorder caused by mutations in the CP gene, leading to a deficiency or absence of Ceruloplasmin, a key plasma protein essential for iron transport. Without treatment, iron accumulates in the brain,
More news about: Kedrion
Nov 27, 2025, 04:00 ET EMA conferisce la Designazione di Farmaco Orfano al trattamento plasmaderivato di Kedrion per l'Aceruloplasminemia Congenita, una malattia genetica rara del metabolismo del ferro
L'Aceruloplasminemia è un disordine autosomico recessivo causato da mutazioni nel gene CP, che determinano una carenza o assenza di Ceruloplasmina, una proteina plasmatica essenziale per il trasporto del ferro. In assenza di trattamento,
More news about: Kedrion
Nov 26, 2025, 14:19 ET Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Nov 26, 2025, 14:13 ET Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more
More news about: Piramal Pharma Solutions
Nov 26, 2025, 12:22 ET Cure SMA Welcomes Broad FDA Approval of Itvisma™ for Spinal Muscular Atrophy, Reinforces Commitment to Patient Access and Support
This newly approved one-time gene therapy delivers a functional SMN1 gene to motor neurons, helping restore SMN protein production and potentially slowing or halting SMA progression. Clinical data showed
More news about: Cure SMA
Nov 25, 2025, 11:00 ET Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities
life-sciences projects from A to Z. The integration supports a growing European life-sciences market shaped by trends such as mRNA platforms, cell and gene therapies, supply-chain resilience, and rising sustainability requirements. In this environment, speed to qualified capacity is a competitive differentiator.
More news about: Exyte
Nov 25, 2025, 09:00 ET Caring Cross and Amrita Research Center Delhi, Amrita Vishwa Vidyapeetham Announce Strategic Partnership to Advance Affordable Cell and Gene Therapies for Underserved Populations Across India
a leading multi-campus, research-intensive university in India. Together, the organizations will develop and implement affordable, scalable cell and gene therapy (CGT) solutions to treat diseases affecting underserved communities, particularly Sickle Cell Disease, Thalassemia, and various cancers.
More news about: Caring Cross
Nov 25, 2025, 09:00 ET Lexogen Successfully Completes Large-Scale Human Primary Cell Next Gen Sequencing Project with Ochre Bio
extensive human liver data, including proprietary gene perturbation and disease atlases, to make causal pathway predictions for target discovery and facilitate the development of RNA therapies. Ochre's proprietary OBELiX software enables interrogation of gene biology in human cells, tissue and whole livers,
More news about: LEXOGEN
Nov 25, 2025, 09:00 ET Lexogen Successfully Completes Large-Scale Human Primary Cell Next Gen Sequencing Project with Ochre Bio
extensive human liver data, including proprietary gene perturbation and disease atlases, to make causal pathway predictions for target discovery and facilitate the development of RNA therapies. Ochre's proprietary OBELiX software enables interrogation of gene biology in human cells, tissue and whole livers,
More news about: LEXOGEN
Nov 25, 2025, 08:05 ET Avantor® Receives 2025 Edison Patent Award for Sustainable Viral Inactivation Technology
challenge by providing a compliant, high-performing, and environmentally responsible alternative for producing monoclonal antibodies, vaccines, and gene therapies."We are honored to be recognized by the R&D Council of New Jersey for this achievement," said Benoit Gourdier, Executive Vice President,
More news about: Avantor and Financial News
Nov 25, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conference
Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
Nov 25, 2025, 05:00 ET Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities
life-sciences projects from A to Z. The integration supports a growing European life-sciences market shaped by trends such as mRNA platforms, cell and gene therapies, supply-chain resilience, and rising sustainability requirements. In this environment, speed to qualified capacity is a competitive differentiator.
More news about: Exyte
Nov 24, 2025, 17:56 ET Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
regardless of SMA treatment history in Phase III studiesOne-time dose of Itvisma replaces SMN1 gene, potentially reducing the need for chronic SMA treatmentGene replacement therapy now available to eligible people of all ages living with SMAEAST
More news about: Novartis
Nov 24, 2025, 16:30 ET Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
inhibitor designed to selectively target tumors with PIK3CA mutations while sparing wild-type PI3Kα. Activating mutations in the PIK3CA gene (which encodes PI3Kα enzyme) are oncogenic drivers present in approximately 40% of hormone receptor positive (HR+)/HER2-negative breast cancers and
More news about: Eli Lilly and Company
Nov 24, 2025, 11:30 ET HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Platform to Crack the Toughest Challenge in Autoimmune and Allergy Drug Development: Multi-target Combination Strategy Optimization
enable evaluation of in vivo interactions, feedback mechanisms, and synergy of multi-target combinations. Using systems biology approaches, including gene regulatory networks, protein-protein interaction networks, and pathway topology analysis, HKeyBio identifies key nodal and bottleneck targets in disease
More news about: HKeyBio
Nov 24, 2025, 10:01 ET Regenerative Medicine Market to Skyrocket to USD 403.86 Billion by 2032 Driven by Cell & Gene Therapy Breakthroughs, Stem Cell Advancements, and Multi-Indication Expansion
pipeline, cell therapy is expected to remain the largest revenue segment through 2032.Gene TherapyGene therapy accounted for 22% (USD 10.7 billion). AAV, lentiviral, CRISPR, and gene-editing platforms are driving commercialization in rare genetic disorders, hematological diseases,
More news about: DataM Intelligence 4 Market Research LLP
Nov 24, 2025, 10:00 ET GEMMABio Announces Clinical Trial Authorization for New SMA1 Gene Therapy
In a talk entitled "Gene Therapy for SMA1: History, R&D on Next Generation Therapy, and the Challenge of Affordability," Dr. Wilson described his team's approach to creating GB221, a next-gen therapy for SMA1. GB221 is a one-time gene therapy that consists of an adeno-associated
More news about: GEMMA Biotherapeutics
Nov 24, 2025, 09:00 ET ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
CEO Jong Sang Ryu commented:"Investor interest in gene-editing therapies targeting cardiovascular diseases is growing rapidly. Eli Lilly's recent acquisition of Verve Therapeutics—whose pipeline includes an Lp(a)-targeted gene-editing program—for $1 billion upfront and up to $300 million
More news about: ToolGen
Nov 24, 2025, 07:30 ET Shapeshifting cancers' masters, unmasked
epigenetic factors that drive tumor growth. In other words, they were looking beyond the genes themselves and into the processes of transcription and gene regulation. Now, in collaboration with CSHL Director of Research
More news about: Cold Spring Harbor Laboratory